Insider Buying: Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Purchases 22,222 Shares of Stock

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Senior Officer Adrian J. Haigh purchased 22,222 shares of the stock in a transaction dated Monday, April 15th. The stock was acquired at an average price of C$2.31 per share, for a total transaction of C$51,332.82.

Fennec Pharmaceuticals Trading Up 0.8 %

TSE:FRX traded up C$0.12 during trading hours on Tuesday, reaching C$14.32. 300 shares of the company were exchanged, compared to its average volume of 754. The company has a debt-to-equity ratio of 881.09, a current ratio of 3.29 and a quick ratio of 10.17. The firm has a market cap of C$387.21 million, a price-to-earnings ratio of -14.04 and a beta of 0.35. Fennec Pharmaceuticals Inc. has a 52-week low of C$9.27 and a 52-week high of C$15.43. The stock has a 50 day simple moving average of C$13.50 and a 200 day simple moving average of C$12.59.

Fennec Pharmaceuticals (TSE:FRX - Get Free Report) last issued its earnings results on Thursday, March 21st. The biopharmaceutical company reported C($0.14) EPS for the quarter, missing analysts' consensus estimates of C$0.02 by C($0.16). Fennec Pharmaceuticals had a negative net margin of 75.50% and a negative return on equity of 1,005.59%. The business had revenue of C$13.25 million during the quarter, compared to analysts' expectations of C$12.88 million. As a group, analysts predict that Fennec Pharmaceuticals Inc. will post 0.4202312 EPS for the current year.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.